Skip to Content Facebook Feature Image

Amprius and Matternet Partner to Advance Drone Delivery

Business

Amprius and Matternet Partner to Advance Drone Delivery
Business

Business

Amprius and Matternet Partner to Advance Drone Delivery

2026-05-19 19:03 Last Updated At:19:11

FREMONT, Calif.--(BUSINESS WIRE)--May 19, 2026--

Amprius Technologies, Inc.(“Amprius” or the “Company”) (NYSE: AMPX), a leader in silicon anode lithium-ion batteries, and Matternet, the world’s only FAA Type Certified drone delivery company, today announced a strategic collaboration to advance the performance and economics of autonomous aerial delivery through high-energy density silicon anode cells. Amprius cells are now deployed in Matternet’s M2 aircraft, and the companies are extending their work to battery solutions optimized for Matternet's next-generation platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519470257/en/

As physical AI moves into the real world — with small, electric autonomous aircraft transporting goods through cities — batteries are becoming a strategic driver of platform performance. In drone delivery, battery performance shapes not only aircraft capability, but also network design, asset utilization, and cost per delivery.

“As the world's leading urban drone delivery player, we partner with the best technology companies in the world to push what's possible,” said Andreas Raptopoulos, Founder and CEO of Matternet. “Amprius delivers best-in-class battery performance, and in drone delivery that translates directly into commercial advantage. Every additional mile of range expands our network coverage. Every minute saved in charging increases fleet utilization. And every gram saved can translate into greater payload capacity. With Amprius, we have the opportunity to engineer that technology around our aircraft, our network model, and our cost-per-delivery targets.”

High-Energy Density Cells for Commercial Drone Delivery

Amprius’ silicon anode cells deliver up to twice the energy density of conventional graphite-based batteries, a critical advantage in aviation, where battery weight directly constrains range, payload, and economics.

For Matternet, this partnership is focused on translating battery performance into commercial operating advantage. Amprius and Matternet will work together to optimize cell selection, form factor, thermal performance, charge rate, and cycle life for Matternet’s next-generation aircraft.

The goal is to go beyond cell-level performance and tune the battery system around Matternet’s aircraft architecture and delivery network, improving aircraft availability, expanding service areas, and reducing cost per delivery as Matternet scales commercial operations.

“At Amprius, we are focused on partnering with category leaders in applications where battery performance changes what is possible,” said Tom Stepien, CEO of Amprius Technologies. “Matternet is exactly that kind of partner, a company with a proven certified platform, real commercial operations, and a clear path to scale. By working closely with Matternet’s engineering team, we can optimize our silicon anode technology for their aircraft, operating models, and cost-per-delivery objectives. That kind of alignment is how battery innovation translates into real-world commercial advantage.”

With Amprius cells already flying in Matternet’s M2 fleet, the companies are now focused on deeper integration for Matternet’s next-generation platform, with Amprius targeting volume production readiness aligned with Matternet’s fleet expansion plans beginning in early 2027.

About Amprius Technologies, Inc.

Amprius Technologies, Inc. is a leader in advanced lithium-ion battery technology, delivering high-energy and high-power silicon-anode batteries with up to twice the energy density, range, and flight time of conventional graphite-based cells. Headquartered in Fremont, California, Amprius operates an R&D lab and pilot manufacturing facility for silicon anodes and cells. To support scalable production, the Company employs a contract manufacturing strategy, enabling rapid capacity expansion with minimal capital investment. Committed to driving innovation in energy storage, Amprius powers next-generation applications in aerospace, defense, and mobility. For additional information, please visit amprius.com and the Company’s LinkedIn page.

About Matternet

Matternet is a leading commercial drone delivery platform for urban and suburban environments. The company builds the Matternet M2 drone, the Matternet Station, and the Matternet Software Platform and operates its technology directly for customers or in partnership with logistics organizations such as UPS. Matternet has achieved many industry firsts, including being the first company authorized for commercial Beyond Visual Line of Sight (BVLOS) drone delivery operations over cities in Switzerland, the first to launch routine revenue-generating drone delivery operations in the U.S., and the first to achieve standard Type Certification and Production Certification from the U.S. Federal Aviation Administration. Matternet is partnered with UPS and Ameriflight, which have received approval from the Federal Aviation Administration to operate the Matternet M2 under Part 135. Matternet has operated commercially for more than a decade, beginning with humanitarian drone delivery missions in 2014, launching B2B healthcare operations in Europe in 2017 and the U.S. in 2019, and expanding into B2C drone delivery operations in Silicon Valley in 2024. To date, Matternet's technology has enabled more than 60,000 commercial flights across dense urban and suburban environments in the U.S. and Europe.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “will” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the performance of Amprius’ products, the benefits of Amprius’ products to its customers and the industry, the potential applications and addressable markets of Amprius’ products, the ability of Amprius to meet its customers’ demand through its contract manufacturers, the demand for Amprius’ products, the ability of Amprius to expand its global business, the prospects of the drone delivery market, the ability of Amprius to meet the demand of the drone delivery market and the ability of Amprius’ contract manufacturers to produce high-performance batteries, and the anticipated collaboration milestones with Matternet. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Amprius’ management and are not predictions of actual performance. Actual results could differ materially from these forward-looking statements as a result of certain risks and uncertainties, including Amprius’ liquidity position; risks related to the rollout of Amprius’ business and the timing of expected business milestones; Amprius’ ability to commercially produce high-performing batteries through its contract manufacturers; the effects of competition on Amprius’ business; supply shortages in the materials necessary for the production of Amprius’ products; and changes in domestic and foreign business, market, financial, political, and legal conditions. More information on these risks and uncertainties can be found in the documents we filed from time to time with the Securities and Exchange Commission (the “SEC”), all of which are available on the SEC’s website atwww.sec.gov. There may be additional risks that Amprius does not presently know or that Amprius currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Except as required by law, Amprius specifically disclaims any obligation to update any forward-looking statements.

Matternet M2 in Mountain View, California.

Matternet M2 in Mountain View, California.

WESTBROOK, Maine--(BUSINESS WIRE)--May 19, 2026--

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that SDMA, a renal biomarker, will be built into Catalyst™ CLIPs, making complete kidney function evaluation part of the most common point-of-care chemistry profiles. Available beginning in June to customers in the United States and Canada, the integration expands access to advanced kidney assessment at scale, enabling veterinarians to identify kidney function loss earlier and act sooner, without disrupting familiar workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519642899/en/

Supported by peer-reviewed studies using the IDEXX SDMA™ Test, SDMA is recognized by the International Renal Interest Society (IRIS) as a key biomarker for evaluating kidney function in pets. 1 Since introducing the IDEXX SDMA™ Test in 2015, IDEXX has performed approximately 119 million SDMA patient tests globally primarily through its reference laboratories and increasingly on the Catalyst platform, 2 underscoring the test’s clinical importance and broad adoption in kidney health evaluation. Results are seamlessly integrated into VetConnect™ PLUS, alongside other diagnostic data.

“SDMA is a clear example of how IDEXX innovates by developing clinically relevant diagnostics and then scaling their impact through platforms veterinarians already use every day,” said Mike Erickson, President and CEO of IDEXX. “Earlier insight enables earlier action, improving outcomes for pets, strengthening care experiences, and supporting durable, long-term growth for veterinary practices and IDEXX.”

Chronic kidney disease (CKD) is common in dogs and cats and frequently unrecognized, particularly early in the disease. Clinical evidence continues to show that including SDMA in routine diagnostic testing enables earlier detection of meaningful declines in kidney function that conventional markers alone may miss. 3–6 In addition, a study, published in the Journal of the American Veterinary Medical Association, found that cats with early-stage CKD treated with a renal diet experienced slower disease progression and improved survival. 7

“Kidney disease is common in both cats and dogs, so early evaluation is important,” said Dr. Christine Kirnos, VMD, The Cat Hospital of Media.* “Making SDMA easier to incorporate into routine in-clinic chemistry testing helps us assess kidney health more consistently and provides meaningful insight during the patient visit.”

For more information, please visit the Catalyst testing web page.

*Dr. Kirnos has received compensation for consulting services she has provided to IDEXX.

References

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

Catalyst SDMA Testing

Catalyst SDMA Testing

Recommended Articles